All In Biotech

Drug Trial Radar · NCT07549386

Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis.

Efficacy and Safety of Etoricoxib 90 mg + Diacerein 50 mg Capsule Compared to Meloxicam 15 mg + Diacerein 50 mg in Patients With Knee and/or Hip Osteoarthritis: A Phase III, Controlled, Randomized, Double-blind, Multicenter Clinical Trial.

Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 123 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

123

Actual

Start

May 24, 2024

Primary completion

Mar 27, 2025

Study completion Oct 15, 2025

Sponsor

Lead sponsor
Laboratorios LiomontIndustry
Sponsor type
Industry
Collaborators
EPIC Research CRO
First posted
Apr 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if fixed-dose combination etoricoxib 90 mg + diacerein 50 mg capsule works to treat knee/hip osteoarthritis-associated pain in adults. It will also learn about the safety of the drug. The main questions it aims to answer are: Does etoricoxib+diacerein reduce pain intensity as per WOMAC scale after 60 days? What medical problems do participants have when taking etoricoxib 90 mg+diacerein 50 mg capsule for 60 days? Researchers will compare the test drug etoricoxib 90 mg+diacerein 50 mg capsule to an active comparator (meloxicam 15 mg + diacereina 50 mg) to see if drug ABC works to treat pain in patients with osteoarthritis. Participants will: Take drug the test or comparator drugs every day for 60 days. Visit the clinic once a month for health and outcomes follow-up. Keep a diary of their symptoms, pain intensity, WOMAC scale, adverse events, rescue medication use, other used drugs, and treatment adherence.

Conditions

  • Pain Management
  • Osteoarthritis

Interventions

  • Etoricoxib 90 mg + diacerein 50 mgDrug

    Once a day for 60 days

  • Meloxicam 15 mg + diacerein 50 mgDrug

    Once a day for 60 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain intensity changeTime frame: At 60 days from baseline

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Grupo Médico ASSET, S.C.

    Mexico City, Mexico City, Mexico

  • RM Pharma Specialists S.A. de C.V.

    Mexico City, Mexico City, Mexico

  • Ainpad, S.C.

    Morelia, Michoacán, Mexico

  • Hospital Centro Quirúrgico Nogalar, S.A. de C.V.

    Monterrey, Nuevo León, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.